胰高血糖素样肽-1受体激动剂与美国2型糖尿病退伍军人物质使用障碍风险:队列研究
该研究利用美国退伍军人事务部电子健康记录,模拟8项平行新用户活性对照目标试验,纳入606434名2型糖尿病退伍军人,随访至多3年。在无SUD史者中,起始GLP-1受体激动剂较SGLT-2抑制剂与酒精、大麻、可卡因、尼古丁、阿片类及其他SUD发生风险降低相关,复合终点HR 0.86(95%CI 0.83-0.88)。在已有SUD者中,GLP-1受体激动剂与SUD相关急诊就诊、住院、死亡、药物过量及自杀意念或企图风险降低相关。作者认为观察性数据提示GLP-1受体激动剂可能具有预防和治疗多种SUD的潜在作用,需进一步评估。
要点
- 无SUD史的2型糖尿病退伍军人中,起始GLP-1受体激动剂较SGLT-2抑制剂与阿片类使用障碍风险降低相关:HR 0.75(95%CI 0.67-0.85),每1000人3年净风险差-0.86(-1.19至-0.52)。
- 同人群中,起始GLP-1受体激动剂较SGLT-2抑制剂与酒精使用障碍风险降低相关:HR 0.82(95%CI 0.78-0.85),每1000人3年净风险差-5.57(-6.61至-4.53)。
- 已有SUD者中,起始GLP-1受体激动剂较SGLT-2抑制剂与SUD相关死亡风险降低相关:HR 0.50(95%CI 0.32-0.79),每1000人3年净风险差-1.52(-2.32至-0.72)。
- 已有SUD者中,起始GLP-1受体激动剂较SGLT-2抑制剂与自杀意念或企图风险降低相关:HR 0.75(95%CI 0.67-0.83),每1000人3年净风险差-9.95(-13.14至-6.77)。
- 治疗依从性分析与治疗起始分析在无SUD史者的新发SUD及已有SUD者的不良结局上结果方向一致。
适用人群与场景
- 美国退伍军人事务部医疗系统内606434名2型糖尿病退伍军人,按有无SUD史分配至两个方案,随访至多3年。
- 方案1(主要试验)纳入524817名起始GLP-1受体激动剂(n=124001)或SGLT-2抑制剂(n=400816)且无SUD史者,评估新发SUD。
- 方案2纳入81617名起始GLP-1受体激动剂(n=16768)或SGLT-2抑制剂(n=64849)且已有SUD者,评估SUD相关不良结局。
研究设计与关键结果
- 设计:利用电子健康记录模拟8项平行新用户活性对照目标试验,其中7项针对各新发SUD结局(方案1),1项针对已有SUD者的不良结局(方案2),采用逆概率加权(标准化死亡比加权)原因别Cox生存模型报告HR和每1000人3年净风险差。
- 无SUD史者中,起始GLP-1受体激动剂较SGLT-2抑制剂与酒精使用障碍风险降低相关:HR 0.82(95%CI 0.78-0.85),NRD每1000人-5.57(-6.61至-4.53)。
- 无SUD史者中,起始GLP-1受体激动剂较SGLT-2抑制剂与大麻使用障碍(HR 0.86,95%CI 0.81-0.90;NRD -2.25,-3.00至-1.50)、可卡因使用障碍(HR 0.80,95%CI 0.72-0.88;NRD -0.97,-1.37至-0.57)、尼古丁使用障碍(HR 0.80,95%CI 0.74-0.87;NRD -1.64,-2.19至-1.09)、阿片类使用障碍(HR 0.75,95%CI 0.67-0.85;NRD -0.86,-1.19至-0.52)、其他SUD(HR 0.87,95%CI 0.81-0.94;NRD -1.12,-1.68至-0.55)及所有新发SUD复合终点(HR 0.86,95%CI 0.83-0.88;NRD -6.61,-7.95至-5.26)风险降低相关。
- 已有SUD者中,起始GLP-1受体激动剂较SGLT-2抑制剂与SUD相关急诊就诊(HR 0.69,95%CI 0.61-0.78;NRD -8.92,-11.59至-6.25)、SUD相关住院(HR 0.74,95%CI 0.65-0.85;NRD -6.23,-8.73至-3.74)、SUD相关死亡(HR 0.50,95%CI 0.32-0.79;NRD -1.52,-2.32至-0.72)、药物过量(HR 0.61,95%CI 0.42-0.88;NRD -1.49,-2.43至-0.55)及自杀意念或企图(HR 0.75,95%CI 0.67-0.83;NRD -9.95,-13.14至-6.77)风险降低相关。
- 治疗依从性分析显示,在无SUD史者的新发SUD及已有SUD者的不良结局上,结果与治疗起始分析方向一致。
证据类型、等级与局限
- 证据类型:利用电子健康记录模拟8项平行新用户活性对照目标试验的观察性队列研究。
- 作者结论:观察性数据提示GLP-1受体激动剂可能在多种SUD的预防和治疗中具有潜在作用,需进一步评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,观察性数据提示GLP-1受体激动剂可能在多种SUD的预防和治疗中具有潜在作用,需进一步评估。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders (SUDs) in people with no history of SUDs (protocol 1) and with reduced risk of SUD related adverse clinical outcomes among people with a pre-existing SUD (protocol 2).
DESIGN: Emulation of eight parallel, new user, active comparator target trials using electronic health records: seven trials for each incident SUD outcome (protocol 1) and one trial for adverse outcomes in people with pre-existing SUD (protocol 2).
SETTING: US Department of Veterans Affairs.
PARTICIPANTS: From a base population of 606 434 US veterans with type 2 diabetes, participants were assigned to one of the two protocols and followed for up to three years. Trial 1 (primary trial) of protocol 1 included 524 817 initiators of GLP-1 receptor agonists (n=124 001) or sodium-glucose cotransporter-2 (SGLT-2) inhibitors (n=400 816). Protocol 2 included 81 617 initiators of GLP-1 receptor agonists (n=16 768) and SGLT-2 inhibitors (n=64 849).
MAIN OUTCOME MEASURES: Incident outcomes were alcohol, cannabis, cocaine, nicotine, opioid, other SUDs, and a composite of these outcomes. Adverse outcomes among participants with pre-existing SUDs included SUD related emergency department visits, SUD related hospital admissions, and SUD related mortality, and drug overdose and suicidal ideation or attempt. Hazard ratios and net three year risk difference (NRD) per 1000 people were reported based on inverse probability weighted (standardised mortality ratio weighted) cause specific Cox survival models.
RESULTS: Compared with initiation of SGLT-2 inhibitors, initiation of GLP-1 receptor agonists was associated with reduced risk of disorders related to alcohol use (hazard ratio 0.82 (95% confidence interval (CI) 0.78 to 0.85); NRD per 1000 people -5.57 (-6.61 to -4.53)), cannabis use (0.86 (0.81 to 0.90), NRD -2.25 (-3.00 to -1.50)), cocaine use (0.80 (0.72 to 0.88), NRD -0.97 (-1.37 to -0.57)), nicotine use (0.80 (0.74 to 0.87), NRD -1.64 (-2.19 to -1.09)), and opioid use (0.75 (0.67 to 0.85), NRD -0.86 (-1.19 to -0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD -1.12 (-1.68 to -0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD -6.61 (-7.95 to -5.26)). Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD -8.92 (-11.59 to -6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD -6.23 (-8.73 to -3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD -1.52 (-2.32 to -0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD -1.49 (-2.43 to -0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD -9.95 (-13.14 to -6.77)). Analyses of treatment adherence showed directionally consistent results with analyses of treatment initiation for both incident SUDs and adverse outcomes among participants with pre-existing SUDs.
CONCLUSIONS: Use of GLP-1 receptor agonists was consistently associated with reduced risks of developing various incident SUDs, suggesting a broad preventive effect across multiple substance types. Use was also associated with reduced risks of adverse clinical outcomes in people with pre-existing SUDs. These observational data suggest a potential role for GLP-1 receptor agonists in both the prevention and the treatment of various SUDs, warranting further evaluation.
参考来源
- Cai M, Choi T, Xie Y, et al. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026. PMID: 41781010. doi:10.1136/bmj-2025-086886
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。